Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson Disease

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• \- Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa

Locations
Other Locations
Egypt
Faculty of Medicine, Mansoura University
RECRUITING
Al Mansurah
Time Frame
Start Date: 2023-11-05
Estimated Completion Date: 2025-12-20
Participants
Target number of participants: 60
Treatments
Active_comparator: control group
Control group (Levo-dopa group, n =30) who received levodopa/carbidopa (250/25 mg) three times daily for 12 months
Active_comparator: Montelukast group
who received levodopa/carbidopa (250/25 mg) three times daily plus Montelukast 10 mg once daily for 12 months
Sponsors
Leads: Mostafa Bahaa

This content was sourced from clinicaltrials.gov